References

Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population

10.1200/jco.2015.66.2866 · 2016 · External reference

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

10.1016/s1470-2045(10)70233-3 · 2010 · External reference

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

10.1038/leu.2017.63 · 2017 · External reference

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

10.1016/s1470-2045(18)30192-x · 2018 · External reference

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)

10.1007/s10147-018-1368-2 · 2019 · External reference

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

10.1016/s2352-3026(15)00196-9 · 2015 · External reference

Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial

10.1016/s2352-3026(19)30235-2 · 2020 · External reference

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

10.1038/s41375-020-0776-2 · 2020 · External reference

Role of cancer immunology in chronic myelogenous leukemia

10.1016/j.leukres.2019.106273 · 2020 · External reference

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

10.1182/blood-2010-12-326843 · 2012 · External reference

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

10.1182/blood-2013-02-483750 · 2013 · External reference

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

10.3324/haematol.2017.165001 · 2017 · External reference

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

10.1038/leu.2016.360 · 2017 · External reference

Innate or adaptive immunity? The example of natural killer cells

10.1126/science.1198687 · 2011 · External reference

KIR3DL1/ HLA-B subtypes govern acute myelogenous leukemia relapse after hematopoietic cell transplantation

10.1200/jco.2016.70.7059 · 2017 · External reference

KIR3DL1 allelic polymorphism and HLA-B epitopes modulate response to Anti-GD2 monoclonal antibody in patients with neuroblastoma

10.1200/jco.2015.64.9558 · 2016 · External reference

Allelic polymorphisms of KIR s and HLA s predict favorable responses to tyrosine kinase inhibitors in CML

10.1158/2326-6066.cir-17-0462 · 2018 · External reference

HLA polymorphisms are associated with treatment-free remission following discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia

10.1158/1535-7163.mct-20-0336 · 2021 · External reference

Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1

10.1038/ng2035 · 2007 · External reference

HLA-A alleles influencing NK cell function impact AML relapse following allogeneic hematopoietic cell transplantation

10.1182/bloodadvances.2020002086 · 2020 · External reference

Decoding the diversity of killer immunoglobulin-like receptors by deep sequencing and a high-resolution imputation method

10.1016/j.xgen.2022.100101 · 2022 · External reference

Implications of HLA diversity among regions for bone marrow donor searches in Japan

10.1111/tan.13881 · 2020 · External reference

Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan

10.1007/s10147-011-0328-x · 2012 · External reference

Investigation of the freely available easy-to-use software “EZR” for medical statistics

10.1038/bmt.2012.244 · 2013 · External reference

Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function

10.1084/jem.20051884 · 2006 · External reference

KIR3DL1 and HLA-B density and binding calibrate NK education and response to HIV

10.4049/jimmunol.1502469 · 2016 · External reference

Killer cell immunoglobulin-like receptor 3DL1 polymorphism defines distinct hierarchies of HLA class I recognition

10.1084/jem.20152023 · 2016 · External reference

The role of the HLA class I α2 helix in determining ligand hierarchy for the killer cell Ig-like receptor 3DL1

10.4049/jimmunol.2001109 · 2021 · External reference

HLA-Bw4-I-80 isoform differentially influences clinical outcome as compared to HLA-Bw4-T-80 and HLA-A-Bw4 isoforms in rituximab or dinutuximab-based cancer immunotherapy

10.3389/fimmu.2017.00675 · 2017 · External reference

HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1

10.1056/nejmoa1200503 · 2012 · External reference

KIR ligand C2 is associated with increased susceptibility to childhood ALL and confers an elevated risk for late relapse

10.1182/blood-2014-05-572065 · 2014 · External reference

KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy

10.1016/j.bbmt.2006.04.008 · 2006 · External reference

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

10.1002/ijc.25233 · 2010 · External reference

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

10.3324/haematol.2011.056853 · 2012 · External reference

The interferon-alpha revival in CML

10.1007/s00277-015-2326-y · 2015 · External reference

Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors

10.1002/ajh.26550 · 2022 · External reference